Stem cell mobilization chemotherapy with gemcitabine is effective and safe in myeloma patients with bortezomib-induced neurotoxicity

Beatrice U. Mueller, Thomas Pabst(University Hospital of Bern), Katja Seipel(University of Bern), Thomas Egger(Solothurner Spitäler), Sandra Keller(University Hospital of Bern), Daniel Betticher, Behrouz Mansouri Taleghani(University of Bern), Daniel Rauch(Washington University in St. Louis)
Leukemia & lymphoma/Leukemia and lymphoma
October 12, 2015
10.3109/10428194.2015.1079315
Cited by 10

Related Papers

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial
|The Lancet|2015|392
Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC)
|Journal of Clinical Oncology|2004|300
Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer
|British Journal of Cancer|1996|220
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial
|The Lancet Respiratory Medicine|2017|184